Pipemidic acid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Pipemidic acid is a quinolone antibiotic indicated in the treatment of susceptible urinary tract infections.
- Generic Name
- Pipemidic acid
- DrugBank Accession Number
- DB13823
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 303.3165
Monoisotopic: 303.133139435 - Chemical Formula
- C14H17N5O3
- Synonyms
- acido pipemidico
- Pipemidic acid
- External IDs
- J01MB04
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Urinary tract infection •••••••••••• ••••• •••••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Pipemidic acid. Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Pipemidic acid. Acemetacin Acemetacin may increase the neuroexcitatory activities of Pipemidic acid. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pipemidic acid. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Pipemidic acid. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Pipemidic acid trihydrate N734WBH1TJ 72571-82-5 URMXYPLWYMOYPG-UHFFFAOYSA-N
Categories
- ATC Codes
- J01MB04 — Pipemidic acid
- Drug Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Urinary
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inhibitors
- Fluoroquinolones
- Nicotinic Acids
- Piperazines
- Potential QTc-Prolonging Agents
- Pyridines
- QTc Prolonging Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Pyrido[2,3-d]pyrimidines / Pyridinecarboxylic acids / Dialkylarylamines / Aminopyrimidines and derivatives / Vinylogous amides / Heteroaromatic compounds / Amino acids / Monocarboxylic acids and derivatives / Dialkylamines / Carboxylic acids show 5 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Carboxylic acid / Carboxylic acid derivative / Dialkylarylamine / Heteroaromatic compound show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- N-arylpiperazine, monocarboxylic acid, amino acid, quinolone antibiotic, pyridopyrimidine (CHEBI:75250)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LT12J5HVR8
- CAS number
- 51940-44-4
- InChI Key
- JOHZPMXAZQZXHR-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H17N5O3/c1-2-18-8-10(13(21)22)11(20)9-7-16-14(17-12(9)18)19-5-3-15-4-6-19/h7-8,15H,2-6H2,1H3,(H,21,22)
- IUPAC Name
- 8-ethyl-5-oxo-2-(piperazin-1-yl)-5H,8H-pyrido[2,3-d]pyrimidine-6-carboxylic acid
- SMILES
- CCN1C=C(C(O)=O)C(=O)C2=CN=C(N=C12)N1CCNCC1
References
- General References
- AIFA Product Information: Urotractin (pipemidic acid) oral capsule [Link]
- External Links
- Human Metabolome Database
- HMDB0041989
- ChemSpider
- 4665
- 8337
- ChEBI
- 75250
- ChEMBL
- CHEMBL30116
- ZINC
- ZINC000000057466
- Wikipedia
- Pipemidic_acid
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 40000000 mg Tablet, film coated Oral 476 MG Tablet, film coated Oral 400 MG Tablet Oral 400 mg Capsule Oral Capsule Oral 200 MG Capsule Oral 400 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.746 mg/mL ALOGPS logP -1.5 ALOGPS logP -1.8 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 5.11 Chemaxon pKa (Strongest Basic) 8.66 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 98.66 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 82.18 m3·mol-1 Chemaxon Polarizability 30.94 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 184.7498044 predictedDarkChem Lite v0.1.0 [M-H]- 182.4194044 predictedDarkChem Lite v0.1.0 [M-H]- 164.55296 predictedDeepCCS 1.0 (2019) [M+H]+ 185.1670044 predictedDarkChem Lite v0.1.0 [M+H]+ 182.3977044 predictedDarkChem Lite v0.1.0 [M+H]+ 166.91096 predictedDeepCCS 1.0 (2019) [M+Na]+ 185.2052044 predictedDarkChem Lite v0.1.0 [M+Na]+ 182.8622044 predictedDarkChem Lite v0.1.0 [M+Na]+ 173.60329 predictedDeepCCS 1.0 (2019)
Enzymes
1. DetailsCytochrome P450 1A2
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable)
- Specific Function
- aromatase activity
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58406.915 Da
References
- Gabriel L, Tod M, Goutelle S: Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90. doi: 10.1007/s40262-016-0371-x. [Article]
- Bertil F. Fredholm (2011). Handbook of Experimental Pharmacology, Volume 200. Springer.
Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23